paul_workman

Institute of Cancer Research names chief executive

pharmafile | November 26, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ICR, Institute of Cancer Research, paul workman 

Professor Paul Workman has been appointed as the chief executive of the Institute of Cancer Research.

Workman who also becomes president of The Institute of Cancer Research (ICR), took the opportunity to announce a commitment to launch a three-pronged attack on cancer’s ability to evolve and evade treatment.

Workman was previously the ICR’s deputy chief executive and director of the Cancer Research UK Cancer Therapeutics Unit, and had been Interim chief executive since July.

Advertisement

An advocate of personalised, precision medicine for cancer he previously held a senior scientific leadership position at AstraZeneca, and was a scientific founder of two biotech companies – Chroma Therapeutics and Piramed Pharma.

Workman says: “It is an incredible honour for me to take the helm at one of the world’s most influential cancer research organisations, and I am determined to repay the faith that has been shown in me by driving further advances for cancer patients.”

Related Content

lab

The Royal Marsden launches AI radiology platform to revolutionise cancer care

The Royal Marsden, a world-leading cancer research centre, has launched a large-scale, AI-powered radiology platform …

cancer-vs-alzheimer-1080x810

ICR identifies key “microRNA” gene driving chemotherapy resistance in cancer

Researchers at the Institute of Cancer Research have discovered that a small RNA molecule known …

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

The Institute for Cancer Research (ICR) called for new measures to increase the speed with …

The Gateway to Local Adoption Series

Latest content